An observational study in Kidney Transplant Recipient, Kidney Transplant; Complications and Transplant Renal Artery Stenosis, sponsored by University of Aarhus. Recruiting at 3 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by University of Aarhus · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Heart Failure by University of Aarhus — 4 open to participants now, 4 under way, none of them phase 3. Heart Failure · University of Aarhus.
Among the 29 studies in Heart Failure by University of Aarhus, this one is one of 2 that started in 2026, is one of 7 observational ones, and was the 28th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →4 of the 29 studies in Heart Failure by University of Aarhus are open now, in 2 countries. Recruiting first, the newest first:
University of Aarhus · Sites in Denmark
Ages 18+
University of Aarhus · Sites in Denmark
Ages 18+
University of Aarhus · Sites in Denmark, Norway
Ages 18+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 23 across the 22 interventional studies, 74 across the 7 observational. Of the 17 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Aarhus is the lead sponsor of 1,303 studies on the registry; 190 are open to participants now.
1 of the studies in Heart Failure by University of Aarhus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05834803University of AarhusEffects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients. | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Heart Failure by University of Aarhus, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Kidney transplantation is performed 250-300 times annually in Denmark and substantially improves survival, quality of life, and reduces the burden of comorbidities in patients with end-stage kidney disease. Despite these benefits, vascular complications, particularly transplant renal artery stenosis (TRAS), remain a major cause of morbidity. Reported incidence of TRAS varies widely (1-23%), reflecting retrospective study designs and inconsistent diagnostic criteria. TRAS are classified into three main types: anastomotic (TRAS-A), post-anastomotic (TRAS-P), and long-segment bend/kink (TRAS-B), with most cases diagnosed within the first two years post-transplant. Severe stenoses can critically impair graft perfusion, leading to reduced renal function and treatment-resistant hypertension.
Percutaneous transluminal angioplasty (PTA) for TRAS is a well-established procedure performed according to the same principles as coronary balloon angioplasty; however, the role of stent placement remains uncertain. PTA without stenting is associated with higher restenosis rates compared to PTA with stenting, yet evidence regarding graft function, survival, and blood-pressure control remains conflicting.
Adverse events related to PTA occur in approximately 10% of patients and are generally mild. Serious adverse events are observed in fewer than 5% of patients and include procedure-related internal bleeding and vascular access-site complications. Severe internal bleeding may require blood transfusion and endovascular vessel occlusion and can, in rare cases, result in loss of the transplanted kidney. Access-site vascular complications may present as bleeding, thrombosis, or pseudoaneurysm.
Against this background, the nationwide prospective multicentre DAN-PTRAIII study aims to establish the true incidence of arterial inflow and venous outflow problems in Danish kidney-transplant recipients, evaluate the efficacy and safety of balloon angioplasty, and explore novel imaging and functional diagnostic methods for predicting treatment response.
The criteria were revised on the registry on Oct 1, 2026. See what changed
National prospective multicenter study with a primary endpoint at 3 months and annual follow-up for up to 10 years post-intervention, evaluating renal function, blood pressure, and clinical events.
Patients with vascular complications, predominantly transplant renal artery stenosis (TRAS) following kidney transplantation, who meet at least one of the clinical inclusion criteria, may be enrolled in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. At least one of the following clinical criteria (1 or 2) must be fulfilled:
Graft dysfunction, defined by at least one of the following:
Persistent resistant hypertension for more than 6 weeks after kidney transplantation, defined as:
Together with at least one of the following radiological criteria:
Doppler ultrasound showing:
2. In cases of strong clinical suspicion of a vascular complication where CT or MR angiography cannot reliably exclude graft artery or vein stenosis, patients may be referred for confirmatory invasive investigations.
Before PTA, catheter-based angiography and translesional pressure measurements are performed to confirm whether the patient meets the radiological eligibility criterion for PTA:
Stenosis 50-69% if at least one of the following criteria is met:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who meet well-defined clinical and radiological criteria for significant vascular complications after kidney transplantation, with transplant renal artery stenosis being by far the most common.
Diagnostic Test: Catheter-based angiography · Diagnostic Test: Measurement of translesional pressure gradients · Diagnostic Test: Intravascular ultrasound (IVUS) · Procedure: Percutaneous transluminal angioplasty (PTA)
Catheter-based angiography performed in accordance with the study protocol.
Measurement of translesional pressure gradients performed in accordance with the study protocol.
Intravascular ultrasound (IVUS) performed in accordance with the study protocol.
Percutaneous transluminal angioplasty (PTA) is performed in accordance with the study protocol. As a general principle, bare-metal stents (BMS) are used. Drug-eluting stents (DES) may be considered when the arterial lumen diameter is \< 4-5 mm. In stenoses where stent placement carries a risk of side-branch occlusion, PTA is performed without stent implantation and most often with a drug-coated balloon (DCB).
Change in measured glomerular filtration rate (mGFR).
Change in measured glomerular filtration rate (mGFR) at 3 months post-PTA compared with baseline.
Time frame: Baseline and 3 months post-PTA.
Change in estimated glomerular filtration rate (eGFR).
Change in estimated glomerular filtration rate (eGFR) measured on day 1, day 7, day 21, at 6 weeks, at 3 and 12 months, and annually thereafter for up to 10 years post-PTA, compared with baseline.
Time frame: Baseline, Day 1, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.
Change in home systolic blood pressure.
Change in home systolic blood pressure measured on day 7, day 21, at 6 weeks, at 3 and 12 months, and annually thereafter for up to 10 years post-PTA, compared with baseline.
Time frame: Baseline, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.
Change in attended automated office systolic blood pressure.
Change in attended automated office systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline.
Time frame: Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in unattended automated office systolic blood pressure.
Change in unattended automated office systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline.
Time frame: Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in 24-hour ambulatory systolic blood pressure.
Change in 24-hour ambulatory systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline.
Time frame: Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in defined daily dose (DDD) of antihypertensive medications.
Change in defined daily dose (DDD) of antihypertensive medications at 3, 12, and 24 months post-PTA compared with baseline.
Time frame: Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in the number of antihypertensive medications.
Change in the number of antihypertensive medications at 3, 12, and 24 months post-PTA compared with baseline.
Time frame: Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in 24-hour ambulatory systolic blood pressure adjusted for changes in antihypertensive medication.
Change in 24-hour ambulatory systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline, adjusted for changes in antihypertensive medication (5 mmHg per DDD).
Time frame: Baseline, 3 months, 12 months, and 24 months post-PTA.
Health status on 12-item Short Form Health Survey (SF-12).
Change in 12-item Short Form Health Survey (SF-12) scores at 3 months post-PTA, compared with baseline. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.
Time frame: Baseline and 3 months post-PTA.
Number of clinical events after PTA.
Cardiovascular and renal events are defined according to the criteria used in the DAPA-CKD study, with the modification that end-stage kidney disease is defined exclusively as either kidney transplantation or chronic dialysis. After PTA treatment, the following clinical events will be recorded for 10 years: 1. Cardiovascular death 2. Renal death 3. Death from non-cardiovascular and non-renal causes 4. Undetermined cause of death 5. Stroke 6. Myocardial infarction 7. Hospitalization for heart failure 8. Reduction in eGFR ≥50% from baseline for ≥28 days, not fulfilling the definition of end-stage kidney disease 9. End-stage kidney disease, defined as kidney transplantation or chronic dialysis for ≥28 days 10. Biopsy-proven rejection 11. Need for repeat PTA due to restenosis or in-stent thrombosis 12. Other relevant clinical events
Time frame: 10 years post-PTA.
Number of adverse events (AEs) occurring within 30 days after the procedure
All adverse events (AEs) occurring within 30 days after the procedure will be recorded and classified according to seriousness, relationship to the procedure, and whether the event occurs within ≤24 hours (periprocedural) or \>24 hours through day 30 (post-interventional): 1. Vessel rupture 2. Vessel dissection 3. Vessel occlusion 4. Vessel perforation 5. Stent thrombosis 6. Embolic events to the kidney or the peripheral circulation (upper or lower extremity, depending on the access route) 7. Pulmonary oedema 8. Major bleeding requiring transfusion 9. Embolisation due to bleeding or another adverse event 10. Nephrectomy due to bleeding or another adverse event 11. Access-site or access-vessel complication requiring additional hospitalisation, blood transfusion, or surgical intervention 12. Requirement for acute dialysis 13. Clinical events, including all-cause mortality, as defined above 14. Other relevant adverse events (AEs)
Time frame: 30 days post-PTA.
Doppler ultrasound.
Diagnostic utility and predictive value for treatment response to PTA.
Time frame: Baseline and 3 months post-PTA.
Invasive pressure measurements across stenoses.
Diagnostic utility and predictive value for treatment response to PTA.
Time frame: Baseline and 3 months post-PTA.
Intravascular ultrasound.
Diagnostic utility and predictive value for treatment response to PTA.
Time frame: Baseline and 3 months post-PTA.
Non-invasive fractional flow reserve computed tomography (FFR-CT) / computational fluid dynamics (CFD) simulation.
Diagnostic utility and predictive value for treatment response to PTA.
Time frame: Baseline and 3 months post-PTA.
Functional magnetic resonance imaging.
Diagnostic utility and predictive value for treatment response to PTA.
Time frame: Baseline and 3 months post-PTA.
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Mar 2031, 58 months after the start.
Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 58 months is above that.
Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.